Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback